Anti-HIV NanoViricide drug applicant shows promise in pet trials NanoViricides, Inc said that its anti-HIV drug applicants demonstrated significant therapeutic efficacy in the recently completed preliminary animal studies. The research were performed at a Bio-Security Level 3 Laboratory facility in Boston, MA viagra side effects on heart . These mouse model research were carried out by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics. Related StoriesStudy: Safe spaces may play critical part in community-based HIV prevention effortsNew research discovers high prevalence of HIV among pregnant refugee ladies in OntarioSafe, effective douche-based rectal microbicide can prevent HIV in gay guys’Dr.
Anti-Infective Drugs Advisory Committee to examine aztreonam for inhalation solution Gilead Sciences, Inc. today announced that aztreonam for inhalation answer, an investigational item for the treating infections due to Pseudomonas aeruginosa in patients with cystic fibrosis , is planned to be reviewed by the Anti-Infective Medicines Advisory Committee of the U.S. Food and Drug Administration on December 10, 2009. Applications for advertising authorization of Cayston are also pending in Australia, Switzerland and Turkey.